Literature DB >> 23820570

QTc interval screening in an opioid treatment program.

David F Katz1, Jun Sun, Vaishali Khatri, David Kao, Becki Bucher-Bartelson, Carol Traut, John Lundin-Martinez, Michael Goodman, Philip S Mehler, Mori J Krantz.   

Abstract

Methadone is highly effective for opioid dependency, but it is associated with Torsade de pointes. Although electrocardiography (ECG) has been proposed, its utility is uncertain, because an ECG-based intervention has not been described. An ECG-based cardiac safety program in methadone maintenance patients was evaluated in a single opioid treatment program from September 1, 2009, to August 31, 2011, in the United States. Time from pretreatment to repeat ECG in new entrants was assessed. The proportion with marked rate-corrected QT (QTc) interval prolongation (>500 ms) and the effect of the intervention on the QTc interval in this group were evaluated. Multivariate predictors of QTc interval change were assessed using a mixed-effects model. Of 531 new entrants, 436 (82%) underwent ≥1 electrocardiographic assessment, and 186 (35%) underwent pretreatment ECG. Median time to follow-up ECG was 43 days but decreased over time (p <0.0001). In 21 patients with QTc intervals >500 ms, the mean QTc interval from peak to final ECG decreased significantly (-55.5 ms, 95% confidence interval -77.0 to -33.9, p = 0.001), and 12 of 21 (57.1%) decreased to lower than the 500-ms threshold. In new entrants with serial ECG, only methadone dose (p = 0.009) and pretreatment QTc interval (p <0.0001) were associated with the magnitude of QTc interval change. In conclusion, this study suggests that the implementation of an ECG-based intervention in methadone maintenance can decrease the QTc interval in high-risk patients; clinical characteristics alone were inadequate to identify patients in need of electrocardiographic screening.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23820570      PMCID: PMC4361084          DOI: 10.1016/j.amjcard.2013.05.037

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

1.  Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc.

Authors:  Martin M Bednar; Edmund P Harrigan; Jeremy N Ruskin
Journal:  Am J Cardiol       Date:  2002-06-01       Impact factor: 2.778

2.  First, do no harm: QT interval screening in methadone maintenance treatment.

Authors:  Mark C Haigney
Journal:  J Addict Dis       Date:  2011-10

3.  QT or not QT, that is the question: routine electrocardiograms for individuals in methadone maintenance treatment.

Authors:  Barry Stimmel
Journal:  J Addict Dis       Date:  2011-10

4.  A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients.

Authors:  J Florian; C E Garnett; S C Nallani; B A Rappaport; D C Throckmorton
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

5.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

6.  Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.

Authors:  Alexander N Katchman; Kelly A McGroary; Michael J Kilborn; Craig A Kornick; Paolo L Manfredi; Raymond L Woosley; Steven N Ebert
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

7.  Vital signs: risk for overdose from methadone used for pain relief - United States, 1999-2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-07-06       Impact factor: 17.586

8.  Torsade de pointes associated with very-high-dose methadone.

Authors:  Mori J Krantz; Laurent Lewkowiez; Helen Hays; Mary Ann Woodroffe; Alastair D Robertson; Philip S Mehler
Journal:  Ann Intern Med       Date:  2002-09-17       Impact factor: 25.391

Review 9.  Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.

Authors:  David Zeltser; Dan Justo; Amir Halkin; Vitaly Prokhorov; Karin Heller; Sami Viskin
Journal:  Medicine (Baltimore)       Date:  2003-07       Impact factor: 1.889

10.  Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.

Authors:  Mori J Krantz; Ilana B Kutinsky; Alastair D Robertson; Philip S Mehler
Journal:  Pharmacotherapy       Date:  2003-06       Impact factor: 4.705

View more
  3 in total

1.  Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.

Authors:  David P Kao; Mark C P Haigney; Philip S Mehler; Mori J Krantz
Journal:  Addiction       Date:  2015-09       Impact factor: 6.526

Review 2.  A literature-based algorithm for the assessment, management, and monitoring of drug-induced QTc prolongation in the psychiatric population.

Authors:  M Zolezzi; L Cheung
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-24       Impact factor: 2.570

Review 3.  The Impact of Opioids on Cardiac Electrophysiology.

Authors:  Erich F Wedam; Mark C Haigney
Journal:  Curr Cardiol Rev       Date:  2016
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.